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This cross-sectional study evaluated the relationship be-
tween 1) functional and structural measurements of neu-
rodegeneration in the initial stages of diabetic retinopathy
(DR) and 2) the presence of neurodegeneration and early
microvascular impairment. We analyzed baseline data of
449 patients with type 2 diabetes enrolled in the European
Consortium for the Early Treatment of Diabetic Retinopathy
(EUROCONDOR) study (NCT01726075). Functional studies
by multifocal electroretinography (mfERG) evaluated neuro-
dysfunction, and structural measurements using spectral
domain optical coherence tomography (SD-OCT) evaluated
neurodegeneration. The mfERG P1 amplitude was more
sensitive than the P1 implicit time and was lower in patients
with Early Treatment of Diabetic Retinopathy Study (ETDRS)
level 20–35 than in patients with ETDRS level <20 (P =
0.005). In 58% of patients, mfERG abnormalities were pre-
sent in the absence of visible retinopathy. Correspondence
between SD-OCT thinning and mfERG abnormalities was
shown in 67% of the eyes with ETDRS <20 and in 83% of
the eyes with ETDRS level 20–35. Notably, 32% of patients
with ETDRS 20–35 presented no abnormalities in mfERG
or SD-OCT. We conclude that there is a link between
mfERG and SD-OCT measurements that increases with
the presence of microvascular impairment. However, a
signiﬁcant proportion of patients in our particular study
population (ETDRS £35) had normal ganglion cell–inner
plexiform layer thickness and normal mfERG ﬁndings. We
raise the hypothesis that neurodegeneration may play
a role in the pathogenesis of DR in many but not in all
patients with type 2 diabetes.
Diabetic retinopathy (DR) is the commonest complication of
diabetes and remains the leading cause of blindness among
working-aged individuals in most developed countries (1).
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Because the global incidence of diabetes is set to rise dra-
matically, from an estimated 382 million people in 2013 to
592 million by 2030 (2), DR will become an even more
serious problem in the coming years.
Tight control of blood glucose levels and blood pressure
are essential in preventing DR development or arresting its
progression. However, current treatments for DR are targeted
at advanced stages when laser photocoagulation, intravitreal
injections of anti–vascular endothelial growth factor agents
or corticosteroids, and vitreoretinal surgery are imple-
mented. All these treatments are invasive, expensive, and
have a signiﬁcant number of secondary effects. Therefore,
new treatments for the early stages of DR are needed (3,4).
DR has been classically considered as a microvascular
disease of the retina. However, growing evidence suggests
that retinal neurodegeneration is an early event in the
pathogenesis of DR, which could contribute to the devel-
opment of microvascular abnormalities (5–8). A reasonable
hypothesis is that therapeutic strategies based on neuro-
protection may be effective not only in preventing or ar-
resting retinal neurodegeneration but also in preventing the
development and progression of the early stages of DR in
terms of microvascular impairment (3,8). This opens up
the possibility of developing topical therapy in the early
stages of DR, when currently established therapies, such
as laser photocoagulation or intravitreal injections of cor-
ticosteroids or anti–vascular endothelial growth factor
agents, are inappropriate (8–10). EUROCONDOR (European
Consortium for the Early Treatment of Diabetic Retinopa-
thy) has been created to implement a large clinical trial
(NCT01726075) using eye drops containing brimonidine
or somatostatin (two previously demonstrated neuroprotec-
tive agents) in the early stages of diabetic retinal disease.
Multifocal electroretinography (mfERG) and spectral
domain optical coherence tomography (SD-OCT) have
both been used in clinical studies to, respectively, measure
neurodysfunction and neurodegeneration. mfERG has been
shown to sensitively detect the presence of neuroretinal
dysfunction in patients with type 1 diabetes even without
any detected blood-retinal barrier leakage measured by
vitreous ﬂuorometry (11). In addition and more impor-
tantly, several authors have found that an increase of the
implicit time (IT) in mfERG is a predictor for the develop-
ment of visible vascular abnormalities over 1-year (12,13)
and 3-year periods (14). However, mfERG is cumbersome
for the patient and time consuming and, therefore, is only
used in the setting of clinical trials. SD-OCT provides ana-
tomical and structural information and is widely available,
easy to perform, and comfortable for the patients. However
there is little information regarding the relationship be-
tween mfERG and SD-OCT and the presence of early mi-
crovascular impairment.
On this basis, the aim of the present work was to analyze
the relationship between baseline mfERG characteristics
and structural abnormalities assessed by SD-OCT, taking
into account the presence and degree of microvascular
abnormalities in the early stages of DR.
RESEARCH DESIGN AND METHODS
Study Subjects
The data for this cross-sectional study were derived from
the 449 patients with type 2 diabetes with no visible DR
(Early Treatment of Diabetic Retinopathy Study [ETDRS]
level ,20) or only early stages of DR (ETDRS level 20–35)
enrolled in the prospective, multicenter, and randomized
EUROCONDOR clinical trial (NCT01726075). This clinical
trial was performed by 11 European ophthalmology clinical
research centers of EUROCONDOR and funded by the
European Commission Seventh Framework Program (Grant
Agreement No. FP7-278040).
In addition to ETDRS level #35, the inclusion criteria
were duration of type 2 diabetes for at least 5 years and age
between 45 and 75 years. Exclusion criteria included pre-
vious laser photocoagulation, retinal degeneration–inducing
diseases (i.e., glaucoma), and refractive error of65 diopters
or more. Eyes with hazy ocular media or inadequate pupil
dilatation that prevented good-quality fundus photography
were excluded. Patients with renal failure (creatinine .124
mmol/L) or HbA1c .10% (86 mmol/mol) in the previous
6 months were also excluded.
The study adhered to the tenets of the Declaration of
Helsinki and was approved by the review boards of
each participant country. Written informed consent
was obtained from all patients before any procedures
were performed.
Each patient underwent a comprehensive ophthalmic
examination, including a review of the medical history, best
corrected visual acuity using the ETDRS protocol, slit-lamp
biomicroscopy, intraocular pressure measurement with
Goldmann applanation tonometry, gonioscopy, and dilated
funduscopic examination, and fasting blood sampling for
blood count and biochemistry analysis. In addition, stan-
dardized seven-ﬁeld color fundus photography, SD-OCT,
and mfERG were performed in all patients. These three
examinations took place within 1 month, and their outputs
were graded by a centralized reading center (Association for
Innovation and Biomedical Research on Light and Image,
Coimbra Ophthalmology Reading Center [AIBILI-CORC]).
Only one eye from each patient was included in the study. If
both eyes met the inclusion criteria, one of the eyes was
chosen randomly.
Grading data were analyzed in two groups according to
severity: patients with ETDRS level ,20 (without micro-
aneurysms) or patients with ETDRS level 20–35 (mild
nonproliferative DR).
mfERG Recording and Analysis
The mfERGs were recorded in the study eye using the RETI-
port/scan 21 (Roland Consult, Berlin, Germany) visual
electrophysiology system. Patients were allowed to eat to
avoid hypoglycemia during the examination. Stimulation
and recording of the mfERG responses were performed
according to the International Society for Clinical Electro-
physiology of Vision guidelines (15,16). After full dilatation
of the pupil with 1% tropicamide and 2.5% phenylephrine,
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and topical anesthesia, a DTL Plus electrode was placed in
the lower conjunctival fornix, a reference skin electrode was
placed near the orbital rim, and a ground skin electrode was
attached to the forehead. The fellow eye was occluded, and
impedances were checked. The patient had to ﬁxate a large
red cross in the stimulation monitor, and the ﬁxation was
controlled using an integral fundus camera using infrared
illumination. The stimulus array consisted of 103 hexagons
displayed at a 60-Hz frame rate centered on the fovea cov-
ering a visual ﬁeld of 30°. The luminance of each hexagon
was independently alternated between black (,2 candela/m2
of luminance) and white (200 candela/m2 of luminance)
according to a pseudorandom binary m-sequence. Each
recording was taken in 12 cycles of ;47 s each with an
artifact rejection level of 10%. Examinations on the baseline
visit were rejected when they presented any of the follow-
ing: “eccentric ﬁxation,” “unsteady ﬁxation,” or “too much
noise compromising the waveform.” Of the 449 examina-
tions, 64 (14%) had to be retaken for one or more of these
reasons. After repeats, all examinations were of sufﬁcient
quality to be included in the study cohort.
Data corresponding to P1 amplitude and IT of 103 hexa-
gons, organized in 6 concentric rings (Fig. 1A) obtained in
patients with type 2 diabetes, were compared with a nor-
mative database of 111 healthy eyes from 76 age-matched
control subjects without diabetes, which was also generated
in the setting of the EUROCONDOR project (17). Healthy
volunteers recruited for the mfERG normative database
were checked for diabetes by a review of the medical history
with recent blood analysis data. In addition, patients with
any known ophthalmic disease were excluded.
OCT Imaging and Analysis
SD-OCT images were acquired according to standardized
acquisition protocols by CIRRUS HD-OCT (Zeiss Meditec),
henceforth designated as CIRRUS, or by Topcon 3D-OCT
2000 (Topcon Corporation), henceforth designated as
Topcon, depending on the equipment available at each site. A
total of 284 patients underwent CIRRUS HD-OCT imaging
(117 patients with ETDRS level ,20 and 167 patients with
ETDRS level 20–35), and 165 patients underwent Topcon
3D-OCT 2000 imaging (76 patients with ETDRS level ,20
and 89 patients with ETDRS level 20–35). OCT scans were
accepted upon conﬁrmation of good quality and the absence
of segmentation errors that compromised quantitative
analysis. Thirteen examinations had to be retaken. After
the repeats, all examinations were of sufﬁcient quality to
be included in the study cohort.
Macular retinal thickness and macular ganglion cell layer–
inner plexiform layer (GCL-IPL) thickness were obtained
from Macular Cube 512 3 128 acquisition of CIRRUS
equipment and from 3D Macula 6 mm3 6 mm acquisition
of Topcon, both acquired when centered on the fovea. Peri-
papillary retinal nerve ﬁber layer (RNFL) thickness was
obtained from CIRRUS using Optic Disc Cube 2003 200 ac-
quisition and from Topcon using the 3D Disc 6.0 mm 3
6.0 mm acquisition.
GCL-IPL and RNFL thicknesses obtained in patients with
type 2 diabetes were compared with normative databases of
the respective equipment manufacturers. The presence of
GCL-IPL or RNFL thinning was considered when the value
was below the mean 22 SDs. The normal RNFL values of
the CIRRUS were calculated by determining the average
value for a 62.5-year-old person (the mean age of the pop-
ulation assessed with that equipment).
To account for differences between Topcon and CIRRUS
equipment, mean values of macular thickness, macular GCL-
IPL thickness, and RNFL thickness at the optic disc were
tested. A conversion factor (mean CIRRUS value divided by
mean Topcon value) was then multiplied for Topcon mea-
surements. Conversion factors were 1.11 for macular retinal
thickness, 1.20 for macular GCL-IPL thickness, and 0.93 for
RNFL thickness at the optic disc (18).
Topographical Coincidence Between mfERG
Abnormalities and SD-OCT Impairment
By superimposing the OCT map of GCL-IPL over the
mfERG hexagonal pattern (Fig. 1B), we analyzed the mfERG
central rings: ring 1, ring 2, and ring 3 (Fig. 1A, red-
delimited area). The P1 amplitude and IT were analyzed by
the number of abnormal hexagons (an altered hexagon was
deﬁned as a hexagon with a z score of 2 or higher for IT
and 22 or lower for amplitude). The relationship between
the presence of abnormal hexagons and thinning of the
GCL-IPL and RNFL layers was examined.
An eye with a central mfERG abnormality was deﬁned as
having at least one abnormal hexagon in any of the three
central rings (Fig. 1).
Statistical Analysis
Descriptive statistics were calculated for all variables. Dif-
ferences between normal values of mfERG amplitude and
IT were inferred with one-way ANOVA. The correlation
between mfERG or GCL-IPL/RNFL thickness parameters
and age, diabetes duration, and HbA1c was explored with
multivariate logistic regression. The relationship between
abnormalities in central mfERG parameters and thinning
of GCL-IPL and/or RNFL was explored with the x2 test.
Figure 1—A: Diagram of the stimulus array used to elicit the mfERGs.
The stimulus consisted of 103 hexagons, organized in 6 concentric
rings, scaled (not represented) to elicit similar amplitudes at all loca-
tions. B: Superimposition of the mfERG stimulus array and the
SD-OCT (GCL+IPL) elliptical annulus grid (blue) on a fundus image,
centered on the fovea. The green-contoured hexagon represents the
central mfERG hexagon, and the two gray circles represent the 10°
and 20° of the mfERG grid.
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Multiple comparison corrections (Bonferroni) were per-
formed where indicated. Signiﬁcance was set at 0.05. Sta-
tistical analysis was performed with Stata 12.1 software
(StataCorp LLC, College Station, TX).
RESULTS
General Description
This cross-sectional analysis of the baseline data from the
EUROCONDOR cohort included 459 patients with type 2
diabetes. The main clinical characteristics of the patients,
taking into account the ETDRS levels, are summarized in
Table 1.
mfERG Abnormalities
A total of 27 of 111 in the control population without
diabetes (24.3%) presented P1 amplitude or IT abnormal
values in at least one of the 19 hexagons that constitute
the three central rings. Patients with diabetes presented a
signiﬁcantly delayed P1 IT from rings 3 to 6 (P , 0.001)
compared with the age-matched control group without di-
abetes (Table 2). We found no inﬂuence of ETDRS levels on
P1 IT. Furthermore, the mean IT (ms) of the six rings was
similar in patients with type 2 diabetes with ETDRS
level ,20 or ETDRS level 20–35 (36.66 6 1.76 vs.
36.64 6 1.76; P = NS).
The mean values of P1 amplitude were signiﬁcantly
lower in the patients with diabetes than in the control
group in all rings (all P , 0.001), and the differences were
even higher in patients with ETDRS level 20–35 than in
patients without microangiopathic abnormalities (ETDRS
,20) (Table 2). Thus, the mean amplitude (nV/deg2) was
signiﬁcantly higher in patients with type 2 diabetes with
ETDRS level ,20 compared with those with ETDRS 20–35
(45.96 6 12.29 vs. 42.77 6 11.29; P = 0.006). The differ-
ence in P1 amplitude between the central and periph-
eral retina (ring 1–6) was signiﬁcantly reduced in patients
with type 2 diabetes compared with subjects without
diabetes (99 6 35 nV/deg2 vs. 109 6 26 nV/deg2; P ,
0.001).
Age was correlated with P1 IT (r = 0.206; P, 0.001), but
no relationship was found between P1 IT or amplitude and
diabetes duration or HbA1c levels.
Finally, the 58% of patients with diabetes with ETDRS
level ,20 presented abnormalities in central mfERG, and
this percentage increased to 66% in patients with diabetes
with ETDRS level 20–35 (P = 0.07).
SD-OCT Abnormalities
The average thickness of the macular GCL-IPL complex
and the average thickness of the peripapillary RNFL were
analyzed in the two DR study groups (ETDRS ,20 and
ETDRS 20–35) and compared with the normal thickness
values given by the normative databases provided by
the equipment manufacturers. The homogenized results
obtained after the previously mentioned conversion factors
were applied are reported in Table 3.
The average GCL-IPL thickness was signiﬁcantly lower
in eyes of patients with diabetes compared with the
normal population (79.4 6 7.3 mm vs. 82.1 6 6.2 mm;
P , 0.001), but there was no difference among patients
with different ETDRS levels (P = NS) (Table 3). Conversely,
the average RNFL at the optic disc presented no signiﬁ-
cant differences between patients’ eyes and the normal
population (89.1 6 9.7 mm vs. 89.8 6 8.5 mm; P = NS).
Values of GCL-IPL or RNFL below the normal range were
present in 41 patients with type 2 diabetes (9.1%).
Table 1—Demographic characteristics of study patients
Total ETDRS ,20 ETDRS 20–35
N = 449 n = 193 n = 256 P*
Age (years) 62.82 6 6.70 64.32 6 6.40 61.70 6 6.80 ,0.001
Sex (% males) 65.9 70.5 62.5 NS
Diabetes duration (years) 11.66 6 5.60 10.57 6 5.10 12.48 6 5.90 ,0.001
Fasting blood glucose (mg/mL) 144 6 52 137 6 46 149 6 55
0.018
Fasting blood glucose (mmol/L) 7.99 6 2.89 7.60 6 2.55 8.27 6 3.05
HbA1c (%) 7.16 6 1.00 7.01 6 0.90 7.28 6 1.10 0.006
HbA1c (mmol/mol) 55 6 10.9 53 6 9.9 56 6 11.5
Hypertension (%) 73.3 73.1 73.4 NS
Dyslipidemia (%) 70.8 74.1 68.4 NS
Current smokers (%) 13.4 13.5 13.3 NS
Microalbuminuria (%) 12.9 11.7 13.7 NS
Cardiovascular disease (%) 20.3 22.3 18.8 NS
Best corrected visual acuity letters score 86.14 6 5.10 85.78 6 5.40 86.42 6 4.80 NS
Data are expressed as mean 6 SD or as indicated. Hypertension was deﬁned as systolic blood pressure/diastolic blood pressure
$140/90 mmHg or current treatment with antihypertensive drugs. Dyslipidemia was deﬁned following the American Diabetes Association
criteria. Cardiovascular disease was deﬁned as a composite end point including coronary artery disease, peripheral artery disease,
and cerebrovascular disease, either self-reported or diagnosed by a physician. *P value between ETDRS ,20 and ETDRS 20–35.
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We found that patients with type 2 diabetes with ETDRS
level 20–35 presented higher values of GCL-IPL thickness
than patients with ETDRS level ,20 (P = 0.018). However,
when the crude data were corrected taking into account
total retinal thickness, no relationship between GCL-IPL
thickness and ETDRS levels was found.
Age was negatively correlated with the average thick-
nesses of both GCL-IPL (r = 20.27; P , 0.001) and RNFL
(r = 20.17; P , 0.001). However, no correlations were
found between GCL-IPL or RNFL thickness and diabetes
duration or HbA1c levels.
Relationship Between SD-OCT and mfERG
In the 193 eyes classiﬁed as having ETDRS level ,20 (i.e.,
with no apparent microvascular abnormalities), central P1
mfERG abnormalities of amplitude or IT were present in
58% of eyes, and only 9% of the eyes showed a decrease
below the normal values of GCL-IPL or RNFL layers thickness.
Similarly, eyes with ETDRS levels 20–35 with microvascular
changes (n = 256) showed central mfERG abnormalities of
amplitude or IT in 66% and thinning of GCL-IPL or RNFL
in 9%.
The relationship between abnormalities in central
mfERG parameters and thinning of GCL-IPL and/or RNFL
is reported in Table 4. In patients with ETDRS level ,20,
67% of those with GCL-IPL or RNFL thinning also pre-
sented mfERG abnormalities. However, in patients with
ETDRS 20–35, 83% of those with GCL-IPL or RNFL thin-
ning also presented mfERG abnormalities (P = 0.07).
Relationship Between Measurements Related to
Neurodegeneration and Early Microvascular
Impairment
The relationship between the measurements related to
neurodysfunction and/or neurodegeneration according
to ETDRS levels are reported in Table 5. We found that
neurodysfunction/neurodegeneration was present in
61% of patients with ETDRS level ,20 and in 68% of pa-
tients with ETDRS level 20–35 (P = 0.13 by x2). Therefore,
neurodegeneration/neurodysfunction abnormalities did not
signiﬁcantly increase in the presence of microvascular ab-
normalities, but as previously mentioned, this latter condi-
tion favored the clustering between mfERG and SD-OCT.
On the one hand, 82 of 256 patients with ETDRS level
20–35 (32%) did not present any abnormalities in mfERG
or SD-OCT examinations, thus suggesting the presence of
primarily a microvascular or a microangiopathic phenotype.
On the other hand, 118 of 193 patients (61%) without
visible microvascular lesions (ETDRS ,20) presented ab-
normalities related to neurodegeneration assessed by
mfERG (58%) or SD-OCT (9%), thus suggesting a neuro-
dysfunctional or neurodegenerative phenotype.
DISCUSSION
The EUROCONDOR study was designed to test the
potential role of two different neuroprotective agents in
arresting the progression of retinal neurodegeneration in
the diabetic retina. The major functional test chosen to
identify and monitor neurodegeneration was mfERG, and
Table 3—SD-OCT values considering DR severity level
Healthy control subjects ETDRS ,20 ETDRS 20–35 All patients
n = 282* n = 193 n = 256 n = 449
GCL-IPL (mm) 82.1 6 6.2 78.6 6 7.3† 79.7 6 7.7† 79.4 6 7.3‡
RNFL (mm) 89.8 6 8.5 88.6 6 10.3 89.9 6 9.8 89.1 6 9.7
Data are expressed as mean 6 SD. *Data referred from normative database of the manufacturers. †Signiﬁcantly different from healthy
subjects on an independent samples t test for P, 0.025 (Bonferroni correction for multiple comparisons). ‡Signiﬁcantly different from healthy
subjects on an independent samples t test for P , 0.05.
Table 2—Values of P1 IT and amplitude of the six concentric rings in healthy control subjects and in patients with type 2 diabetes
Healthy control subjects ETDRS ,20 ETDRS 20–35
Ring n = 76 n = 193 n = 256 P*
IT (ms) 1 42.0 6 3.5 42.1 6 4.7 42.1 6 4.7 0.63
2 36.0 6 2.0 36.6 6 2.9 36.6 6 2.8 0.08
3 34.2 6 1.8† 35.6 6 2.0 35.6 6 1.7 ,0.001
4 33.5 6 1.8† 35.0 6 1.7 35.1 6 1.7 ,0.001
5 33.4 6 1.7† 35.0 6 1.7 35.1 6 1.9 ,0.001
6 33.8 6 1.8† 35.3 6 1.9 35.4 6 1.7 ,0.001
Amplitude (nV/deg2) 1 128.9 6 26.4† 118.4 6 40.1 111.5 6 35.8 ,0.001
2 70.2 6 13.3† 56.3 6 16.1‡ 52.6 6 14.6§ ,0.001
3 46.8 6 8.3† 37.7 6 10.7‡ 34.5 6 9.1§ ,0.001
4 32.6 6 5.7† 26.7 6 8.1‡ 24.4 6 6.8§ ,0.001
5 25.0 6 4.7† 20.5 6 6.4‡ 18.8 6 5.5§ ,0.001
6 20.3 6 4.0† 16.3 6 5.4 15.3 6 5 ,0.001
Data are expressed as mean 6 SD. *P value from ANOVA. †Signiﬁcantly different from ETDRS ,20 and ETDRS 20–35. ‡Signiﬁcantly
different from healthy control subjects and ETDRS 20–35. §Signiﬁcantly different from healthy control subjects and ETDRS ,20.
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structural abnormalities were evaluated by SD-OCT. In
this report, the baseline data have been evaluated to study
the relationship between neurodegeneration assessed by
mfERG (functional abnormalities) and SD-OCT (structural
damage) as well as their relationship with the absence
(ETDRS level ,20) or presence (ETDRS levels 20–35) of
early microvascular retinal impairment.
mfERG is a highly sensitive method that allows for an
objective and quantitative measurement of retinal function.
This technique, when performed following a well-deﬁned
protocol by trained examiners, offers reliable results and may
be particularly valuable for evaluating retinal neuron impair-
ment. The baseline data collected from EUROCONDOR
participants showed alterations of the mfERG in almost
60% of patients with type 2 diabetes with no apparent
fundus abnormalities (ETDRS level ,20). These ﬁndings
are in agreement with previous studies (11–14) and support
the concept that functional impairment related to neuro-
degeneration is an early event in the diabetic retina. How-
ever, mfERG abnormalities were not found in 34% of
patients with diabetes with early microvascular impair-
ment (ETDRS 20–35). Therefore, in some of these patients,
retinal neurodegeneration does not appear to play an essen-
tial role in the development of DR, at least when assessed by
mfERG.
The most widely used mfERG parameter in the setting
of diabetes has been the P1 IT because of its lower
variability compared with P1 amplitude. However, our
results provide evidence that P1 amplitude, rather than P1
IT, is the most sensitive parameter. We found a decrease of
P1 amplitude from the central to the peripheral retina
(from ring 1 to ring 6) in patients with type 2 diabetes and
in healthy control subjects. Our results agree with previous
studies performed in Indian (19) and Japanese (20) normal
subjects. The geographical distribution of cones (higher in
the central retina and lower in the periphery) supports
these ﬁndings (21,22). Our results suggest that the differ-
ence in P1 amplitude from the central to the peripheral
retina could be a useful parameter for monitoring the neu-
rodegenerative process, but further studies to examine this
issue are needed.
One important issue to be considered when analyzing
mfERG is the ﬂuctuation response that could occur depend-
ing on the glycemic excursions. In the current study,
patients with poor glycemic control (HbA1c .10%) were
excluded, the mean 6 SD fasting glucose was 7.99 6
2.89 mmol/L, HbA1c was 7.1 6 1.0% (55 6 10.9 mmol/mol),
and more importantly, we did not observe any rela-
tionship between fasting glycemia or HbA1c levels with
Table 5—Relationship between the measurements related to neurodysfunction and/or neurodegeneration according to ETDRS
levels
No microangiopathy Microangiopathy
ETDRS ,20 (n = 193) ETDRS 20–35 (n = 256)
No NRD NRD P No NRD NRD P
N (%) 75 (39) 118 (61) 82 (32) 174 (68)
Age (years) 63.1 6 6.7 65.1 6 6.0 0.04 59.7 6 7.5 62.6 6 6.1 0.003
BMI (kg/m2) 30.2 6 5.6 31.6 6 5.3 NS 30.0 6 5.2 30.6 6 5.6 NS
Diabetes duration (years) 11 6 5.5 10.3 6 4.8 NS 11.8 6 4.8 12.8 6 6.3 NS
Fasting blood glucose (mg/dL) 129 6 44 142 6 47
0.07
148 6 56 149 6 55
NS
Fasting blood glucose (mmol/L) 7.16 6 2.44 7.88 6 2.61 8.21 6 3.11 8.27 6 3.05
HbA1c (%) 7.05 6 0.79 6.98 6 0.96 NS
7.16 6 0.98 7.32 6 1.08
NS
HbA1c (mmol/mol) 54 6 8.7 53 6 10.6 55 6 10.7 56 6 11.3
Mean IT (ms) 36.16 6 1.41 36.96 6 1.88 0.001 35.93 6 1.41 36.98 6 1.81 ,0.001
Mean amplitude (nV/deg2) 51.35 6 11.11 42.56 6 12.89 0.012 48.61 6 9.00 40.12 6 11.22 ,0.001
GCL-IPL (mm) 80.47 6 5.92 77.39 6 7.77 0.004 82.09 6 6.77 78.66 6 7.90 0.001
RNFL (mm) 90.70 6 9.17 87.35 6 9.67 0.018 92.18 6 8.31 88.22 6 10.28 0.003
Data are expressed as mean 6 SD or as indicated. NRD, neurodysfunction and/or neurodegeneration.
Table 4—Correspondence between abnormalities in central
mfERG and SD-OCT parameters
mfERG, n (%)
Normal Abnormal P
All patients (N = 449)
SD-OCT, n (%) 0.06
Normal 160 (35.6) 248 (55.2)
Abnormal 10 (2.2) 31 (6.9)
ETDRS ,20 (n = 193)
SD-OCT, n (%) 0.41
Normal 76 (39.4) 99 (51.3)
Abnormal 6 (3.1) 12 (6.2)
ETDRS 20–35 (n = 256)
SD-OCT, n (%) 0.07
Normal 84 (32.8) 149 (58.2)
Abnormal 4 (1.6) 19 (7.4)
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mfERG abnormalities. For all these reasons, a potential
inﬂuence of glycemic ﬂuctuations on mfERG seems very
unlikely.
The most important structural damage of the retina
detected by SD-OCT was a thinning of the GCL-IPL and
RNFL layers, although in far fewer number of eyes/patients
compared with mfERG abnormalities. However, mfERG
abnormalities were absent in approximately one of three
patients with ETDRS level ,20 in whom GCL-IPL or RNFL
thickness were below the normal range. In this regard,
mfERG is a measurement of cone photoreceptor and bipolar
cell function (22) and may not represent inner retinal de-
fects. Therefore, the observed dissociation between the two
tests is not entirely surprising. In addition, whereas the
thinning of the neuroretina assessed by SD-OCT reﬂects
neural loss, mfERG abnormalities could only be the conse-
quence of neurodysfunction caused by glial activation.
This ﬁnding supports the complementarity of using
both examinations when neurodysfunction/neurodegenera-
tion is being assessed. One result that merits comment is the
absence of further GCL-IPL or RNFL thickness reduction
when microangiopathy was detected, whereas P1 amplitude
was signiﬁcantly reduced. In fact, an increase of GCL-IPL
thickness was detected in patients with ETDRS level 20–35
compared with patients with ETDRS level ,20. This could
be attributed to the increased sensitivity of functional
mfERG rather than structural SD-OCT abnormalities when
assessing the neurodegenerative process. However, another
possibility is that vascular leakage, predominant in the inner
nuclear layers in the initial stages of diabetic retinal disease,
leads to an increase in overall thickness of the retina and acts
as a confounding factor that masks thinning of the GCL-IPL
complex. In a recent study that monitored a large cohort of
diabetic eyes with nonproliferative retinopathy for 1 year,
thinning of GCL-IPL and RNFL was also found. However,
this increase in thinning was masked by the presence
of retinal edema resulting from leakage from the retinal ves-
sels and an increase in the retinal extracellular space extend-
ing to the inner retinal layers (23). In this regard, when the
GCL-IPL thickness was corrected in our study by taking into
account total retinal thickness, the inverse relationship be-
tween GCL-IPL thickness and progression from ETDRS level
,20 to ETDRS level 20–35 disappeared.
The mfERG and SD-OCT abnormalities were both
related to age. This ﬁnding was expected as a result of
the direct relationship between the neurodegenerative
process and age. The lack of association between mfERG
and SD-OCT measurements of neurodegeneration and
HbA1c could be attributed to the well-established concept
that HbA1c levels taken at a certain point in time do not
necessarily represent the previous history of metabolic con-
trol of the patient, and therefore, biomarkers of long-term
glycation might be more informative than HbA1c levels. In
addition, the excellent control of blood glucose levels in this
cohort (mean HbA1c = 7.16% [55.2 mmol/mol] and only
30% patients .7.5% [58.5 mmol/mol]) could also have
contributed to this result.
Little is known regarding the relationship between func-
tional and structural abnormalities in the setting of diabetes-
induced retinal neurodegeneration. In the current study, we
found an impairment of the retinal function in the initial
stages of retinal disease in patients with type 2 diabetes
with a good correspondence between central mfERG changes
(three central rings) and SD-OCT structural damage (thin-
ning of GCL-IPL and RNFL layers), which increased with the
presence of early DR. As previously reported in this cohort,
these neuroretinal abnormalities have clinical implications in
vision-related quality of life (24).
A notable ﬁnding was that 32% of the patients with
visible microvascular disease in color fundus photography
(ETDRS 20–35) did not present any functional or structural
abnormality related to neurodegeneration. On the one
hand, this ﬁnding suggests the presence of a signiﬁcant
proportion of patients with a primarily microvascular or
microangiopathic phenotype in which the role of neurode-
generation remains to be elucidated. On the other hand,
61% of the patients without visible microvascular disease
(ETDRS ,20) presented abnormalities related to neurode-
generation assessed by mfERG or SD-OCT, thus suggesting
the presence of a neurodysfunctional or neurodegenerative
phenotype. Prospective follow-up will determine whether
this phenotype will be more prone to develop microvascular
disease than in those patients without neurodegenerative
abnormalities. The identiﬁcation of these two phenotypes is
an important issue because of its therapeutic implications,
particularly when analyzing the potential effect of neuro-
protective agents.
In conclusion, functional abnormalities can be detected
by mfERG in almost 60% of patients with type 2 diabetes
with no apparent fundus abnormalities, and these changes
antedate the structural damage measured by SD-OCT.
However, this is not a universal pattern, and the develop-
ment of microvascular disease in a signiﬁcant proportion of
these patients is not preceded by any neurodegenerative
abnormality detected via the methods used in this study
(SD-OCT and mfERG). Overall, our ﬁndings open up the
hypothesis that neurodegeneration could play a role in the
pathogenesis of early stages of DR in a large proportion but
not in all patients with type 2 diabetes.
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